TY - JOUR T1 - Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01462-2017 VL - 50 IS - 5 SP - 1701462 AU - Emanuele Pontali AU - Giovanni Sotgiu AU - Simon Tiberi AU - Lia D'Ambrosio AU - Rosella Centis AU - Giovanni B. Migliori Y1 - 2017/11/01 UR - http://erj.ersjournals.com/content/50/5/1701462.abstract N2 - The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18].Bedaquiline is well tolerated: evidence indicates a minority of patients discontinue use due to QT extension http://ow.ly/9NRT30fNv4y ER -